CGD Experts Discuss MVAC Blueprint To Create Market For New TB Drugs

Center for Global Development: A Final MVAC Blueprint — and the Start of an R&D Revolution?
Rachel Silverman, policy fellow at CGD, and colleagues discuss the Market-Driven, Value-Based Advance Commitment (MVAC) proposal, “a mechanism to create and guarantee a market for better TB treatment, if and when such a treatment becomes available,” and highlight a blueprint outlining its rationale and basic structure. The authors write, “We believe the MVAC is an innovative mechanism that can help to kickstart the R&D revolution needed to tackle diseases of the poor whilst also creating the beginnings of a marketplace for innovative products in emerging markets. We are proposing first use of this mechanism for new drugs for TB” (2/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.